Families, clinicians, payors, and policy-makers continue to grapple with the very complex problem of caring for people with chronic diseases. These patient populations defy the status quo in health care, which is based on discrete and billable episodes of care that, for the most part, take place within the walls of physicians’ offices and other health care facilities. Patients with chronic illnesses, however, need frequent, if not continuous care where they live and work.
Philips Homes In on Respironics: Fills Gaps in Care Continuum
No company has done more to wrap its arms around the whole area of patient monitoring--both in and out of the hospital--than Philips Medical Systems. Since early 2006, Philips has made at least seven acquisitions that have helped it create the infrastructure for a telehealth approach to disease management, including monitoring equipment, IT, and emergency response services. To close out 2007, Philips announced an additional acquisition: a $5.1 billion all-cash offer for respiratory therapy provider Respironics, to buy the leading company in a universe of only three independent companies focused on obstructive sleep apnea, the fastest growing market in home health monitoring.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.